Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.


Evolving Standards of Care


  • Liquid Biopsy: The Key Weapon for Real-Time Monitoring of Patients With NSCLC 

    Liquid Biopsy: The Key Weapon for Real-Time Monitoring of Patients With NSCLC 

    Christian Rolfo, MD, PhD, MBA, Dr.hc., et al.
    Evolving Standards of Care

    Tissue still represents the “gold standard” biosource for molecular profiling of lung cancer. However, the use of tissue samples in clinical practice is associated with several technical and biological limitations. For instance, tissue specimens can provide only a small picture of the complex molecular landscape of patients with lung cancer, freezing the situation at the…


  • PD-L1 Blockade Reinvigorates Dendritic Cells for Antitumor Immunity

    PD-L1 Blockade Reinvigorates Dendritic Cells for Antitumor Immunity

    Evolving Standards of Care

    In reference to: Mayoux M, Roller A, Pulko V, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):eaav7431.  Checkpoint blockade with PD-1 or PD-L1 inhibitors has shown durable clinical responses across many cancer types. Previously, it had been generally believed that PD-1/PD-L1 blockade generates antitumor immunity by reinvigorating the…


  • Research’s Race to Stop a Pandemic

    Research’s Race to Stop a Pandemic

    Evolving Standards of Care

    Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021.  “To put that in perspective, if I search for EGFR, a major area of cancer research, there are just over 96,000 results in the 40 years since…


  • Impactful Multidisciplinary Care Not Out of Reach in Community Settings

    Impactful Multidisciplinary Care Not Out of Reach in Community Settings

    Evolving Standards of Care

    In 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic criteria for lung adenocarcinoma, but it also highlighted “the importance of a close collaboration between oncologist, pathologist, molecular biologist, radiologist and surgeons …  to offer…


  • CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients With Lung Cancer

    CT Findings of COVID-19 Pneumonia and Mimicking Diseases in Patients With Lung Cancer

    Soon Ho Yoon, MD, PhD, et al.
    Evolving Standards of Care

    The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung cancer accounts for a considerable portion of these malignancies. Patients with lung cancer have often experienced severe disease when they contract COVID-19,2 which highlights the…


  • EGFR/ALK-Mutated NSCLC: Using Real-world Therapeutic Practices to Help Answer Real-world Therapeutic
            Questions

    EGFR/ALK-Mutated NSCLC: Using Real-world Therapeutic Practices to Help Answer Real-world Therapeutic Questions

    Evolving Standards of Care

    ILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction with four other institutions, on a phase II study evaluating pembrolizumab plus chemotherapy in patients with EGFR mutation positive and ALK translocated NSCLC previously treated…


  • Increasing Understanding about the Role Biosimilar Agents in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 1 of 2) 

    Increasing Understanding about the Role Biosimilar Agents in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 1 of 2) 

    Evolving Standards of Care

    In September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung cancer, there are many others in development. Gary Lyman, MD, is Professor of Public Health Sciences and Clinical Research at the Fred Hutchinson Cancer Research…


  • Interstitial Lung Abnormality, Interstitial Lung Disease, and Lung Cancer

    Interstitial Lung Abnormality, Interstitial Lung Disease, and Lung Cancer

    Hiroto Hatabu, MD, PhD, FACR, et al.
    Evolving Standards of Care

    As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with COVID-19 pneumonia or radiation pneumonitis. Recently, clinicians have begun to notice the increased incidence  of DRP associated with molecular targeted therapy and immunotherapy in patients…


  • Pembrolizumab Is Active in Lung Cancer Brain Metastases

    Pembrolizumab Is Active in Lung Cancer Brain Metastases

    Evolving Standards of Care

    In Reference To: Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5)655-663. Many studies over the past several years have clearly demonstrated the efficacy of PD-1 and PD-L1 inhibitors for NSCLC,…


  • Using Tumor Radiomic Features To Predict NSCLC Chemotherapy Response

    Using Tumor Radiomic Features To Predict NSCLC Chemotherapy Response

    Michelle Hershman, MD, et al.
    Evolving Standards of Care

    IN REFERENCE TO: Khorrami M, Jain P, Bera K, et al. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer. 2019;135:1-9.